3PO
Based on 31 publication(s) in Google Scholar
3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC50s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+ and NADH. 3PO can be used for the research of cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.85%
- CAS 番号: 18550-98-6
- 分子式: C13H10N2O
- 分子量:210.23
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
MedChemExpress(MCE)の使用を引用している文献 3PO
More- Signal Transduct Target Ther. 2022 Sep 1;7(1):303. [Abstract]
- Nat Metab. 2022 Oct;4(10):1306-1321. [Abstract]
- Adv Sci (Weinh). 2024 Dec 25:e2407134. [Abstract]
- Redox Biol. 2021 Oct:46:102082. [Abstract]
- Acta Pharmacol Sin. 2024 Dec;45(12):2579-2597. [Abstract]
- J Transl Med. 2026 Apr 22;24(1):571. [Abstract]
- Blood Adv. 2024 May 14;8(9):2312-2325. [Abstract]
- Arch Toxicol. 2022 Nov;96(11):2913-2926. [Abstract]
- J Agric Food Chem. 2021 Nov 3;69(43):12862-12869. [Abstract]
- Ecotoxicol Environ Saf. 2024 Feb:271:115994. [Abstract]
- Cancer Cell Int. 2024 Jan 6;24(1):12. [Abstract]
- Cell Prolif. 2021 Jul;54(7):e13058. [Abstract]
- Pharmaceuticals (Basel). 2025 Dec 17;18(12):1902. [Abstract]
- Biomolecules. 2023 Jul 3;13(7):1072. [Abstract]
- Int Immunopharmacol. 2026 May 14:182:116841. [Abstract]
- Am J Physiol Cell Physiol. 2025 Feb 5. [Abstract]
- mSystems. 2025 Dec 11:e0063225. [Abstract]
- Poult Sci. 2024 Jun;103(6):103717. [Abstract]
- Virol Sin. 2025 Nov 21:S1995-820X(25)00161-0. [Abstract]
- Fish Shellfish Immunol. 2022 Oct:129:22-29. [Abstract]
- ACS Chem Neurosci. 2019 May 15;10(5):2332-2344. [Abstract]
- Vet Res. 2025 Apr 30;56(1):94. [Abstract]
- Food Chem Toxicol. 2021 Feb:148:111926. [Abstract]
- Toxicol Appl Pharmacol. 2019 Apr 1:368:26-36. [Abstract]
- J Inorg Biochem. 2022 Apr 20;233:111838. [Abstract]
- Front Biosci (Landmark Ed). 2023 Nov 3;28(11):277. [Abstract]
- Vet Parasitol. 2025 Apr 15:337:110471. [Abstract]
- Res Sq. 2024 Nov 11.
- SSRN. 6 Oct 2022.
- Research Square Print. 2022 May.
- Research Square Preprint. 2022.
-
ELISA
-
Flow Cytometry
-
IHC
-
Cell Autophagy Assay
-
Cell Autophagy Assay
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Epithelial cell | IC50 |
1.4 μM
Compound: 1; 3PO
|
Cytotoxicity against human Epithelial cell assessed as cell growth inhibition
Cytotoxicity against human Epithelial cell assessed as cell growth inhibition
|
[PMID: 32679452] |
3PO (0-33 μM; 0-36 h) inhibits Jurkat cells proliferation by influence cell cycle[1]. 3PO (10 μM/L; 0-36 h) suppresses glycolytic flux to lactate in Jurkat cells[1]. 3PO (10 μM/L; 0-36 h) inhibits cellular proliferation of transformed tumor cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Jurkat cells
-
Concentration:0.3, 1, 3, 10 and 33 μM
-
Incubation Time:0, 4, 8, 16, 24 and 36 hours
-
Result:Inhibited Jurkat T cells proliferation by G2-M phase cell cycle arrest.
-
Cell Line:Jurkat cells
-
Concentration:0.3, 1, 3, 10 and 33 μM
-
Incubation Time:0, 4, 8, 16, 24 and 36 hours
-
Result:Decreased lactate secretion, NADH, NAD+ and ATP in Jurkat cells.
-
Cell Line:Jurkat, K562, HL-60, MDA-MB231, HL-60, HeLa, Melanoma and Lewis Lung
-
Concentration:0-20 μM
-
Incubation Time:0, 4, 8, 16, 24 and 36 hours
-
Result:Inhibited solid tumor and hematologic cell lines with IC50s of 1.4-24 μM/L.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C57Bl/6 mice with Lewis lung carcinoma xenografts[1]
-
Dosage:0.07 mg/g
-
Administration:Intraperitoneal injection; 0.07 mg/g once a day; for 14 days
-
Result:Suppressed the growth of Lewis lung carcinoma xenografts in C57Bl/6 mice compared to the control group.
-
Animal Model:Female BALB/c athymic mice with MDA-MB231 human breast adenocarcinoma xenografts[1]
-
Dosage:0.07 mg/g
-
Administration:Intraperitoneal injection; 0.07 mg/g three sequential daily injections of either DMSO or 3PO followed by 3 off days; for 14 days
-
Result:Suppressed xenograft tumorigenic growth of MDA-MB231 cells compared with the controls.
-
Animal Model:Female BALB/c athymic mice with HL-60 leukemia xenografts[1]
-
Dosage:0.07 mg/g
-
Administration:Intraperitoneal injection; 0.07 mg/g two daily injections followed a 7-day rest; for 14 days
-
Result:Suppressed xenograft tumorigenic growth of HL-60 leukemia compared with the controls, especially from the second administration cycle.
-
Animal Model:Female C57Bl/6 mice with Lewis lung carcinoma xenografts[1]
-
Dosage:0.07 mg/g
-
Administration:Intraperitoneal injection; once
-
Result:Decreased Fru-2,6-BP and glucose uptake in C57Bl/6 mice compared to control group.
化学情報
-
CAS 番号 18550-98-6
-
性状 Solid
-
分子量 210.23
-
分子式 C13H10N2O
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC=NC=C1)/C=C/C2=CC=CN=C2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (31)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Suppression of PFKFB3-driven glycolysis restrains endothelial-to-mesenchymal transition and fibrotic response. [Abstract]2022 Sep 1;7(1):303. PMID: 36045132 -
Nat Metab
HK1 from hepatic stellate cell-derived extracellular vesicles promotes progression of hepatocellular carcinoma. [Abstract]2022 Oct;4(10):1306-1321. PMID: 36192599 -
Adv Sci (Weinh)
Fatty Acid Oxidation-Glycolysis Metabolic Transition Affects ECM Homeostasis in Silica-Induced Pulmonary Fibrosis. [Abstract]2024 Dec 25:e2407134. PMID: 39721015 -
Redox Biol
Pharmaceutical targeting of succinate dehydrogenase in fibroblasts controls bleomycin-induced lung fibrosis. [Abstract]2021 Oct:46:102082. PMID: 34343908 -
Acta Pharmacol Sin
SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization. [Abstract]2024 Dec;45(12):2579-2597. PMID: 39294445
3PO purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Dec;45(12):2579-2597. [Abstract]
BMDMs isolated from C57BL/6J mice were incubated for 12 h with 10 μmol/L 3PO or vehicle in the presence of LPS (100 ng/mL) + IFN-γ (50 ng/mL). The supernatant levels of pro-inflammatory and anti-inflammatory cytokines measured by ELISA. n = 6 per group. The results showed that 3PO significantly reduced the supernatant levels of TNF-α and IL-6.
3PO purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Dec;45(12):2579-2597. [Abstract]
BMDMs isolated from C57BL/6J mice were incubated for 12 h with 10 μmol/L 3PO or vehicle in the presence of LPS (100 ng/mL) + IFN-γ (50 ng/mL). The MFI of CD80 and CD86, and CD206 detected by flow cytometry. n = 3 per group. n = 6 per group. The results showed that 3PO significantly reduced the MFI of CD86, whereas it markedly increased the MFI of CD206.
-
J Transl Med
Vitamin D attenuates the progression of pulmonary fibrosis via inhibiting thymidine kinase 1/PFKFB3-driven glycolysis. [Abstract]2026 Apr 22;24(1):571. PMID: 42021376 -
Blood Adv
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. [Abstract]2024 May 14;8(9):2312-2325. PMID: 38295283 -
Arch Toxicol
CuO-NPs-triggered heterophil extracellular traps exacerbate liver injury in chicks by promoting oxidative stress and inflammatory responses. [Abstract]2022 Nov;96(11):2913-2926. PMID: 35962800
3PO purchased from MedChemExpress. Usage Cited in: Arch Toxicol. 2022 Nov;96(11):2913-2926. [Abstract]
Cells were intervened with specific inhibitors Ritonavir, 3PO (24 μM), STF-31, NSC23766, AZD3965, and 3-bromopyruvic acid for 30 min, and then incubated for 2 h with CuO-NPs (20 μg/mL). The results showed that 3PO significantly inhibited the release of HETs.
-
J Agric Food Chem
Glycolysis and Reactive Oxygen Species Production Participate in T-2 Toxin-Stimulated Chicken Heterophil Extracellular Traps. [Abstract]2021 Nov 3;69(43):12862-12869. PMID: 34694797
3PO purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2021 Nov 3;69(43):12862-12869. [Abstract]
T-2-triggered HET formation is dependent on PFKFB3, lactate transport, and hexokinase II. Heterophils were stimulated with T-2 (80 ng/mL) for 90 min in the inhibitors 3PO (24 μM), AZD3965, and 3-Bromopyruvic (n = 5). Zymosan (1 mg/mL) was the positive control. The results showed that 3PO significantly inhibited HET formation.
-
Ecotoxicol Environ Saf
Paracrine signaling of ferroptotic airway epithelium in crystalline silica-induced pulmonary fibrosis augments local fibroblast activation through glycolysis reprogramming. [Abstract]2024 Feb:271:115994. PMID: 38262094 -
Cancer Cell Int
RORα inhibits gastric cancer proliferation through attenuating G6PD and PFKFB3 induced glycolytic activity. [Abstract]2024 Jan 6;24(1):12. PMID: 38184549
3PO purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 Jan 6;24(1):12. [Abstract]
RORα deletion promotes GC proliferation induced by 3PO and DHEA in vivo The expression levels of Ki-67 and PCNA were detected through immunohistochemistry stain and MOD method in subcutaneous tumor of mice. Original 200 and 400 magnification. Scale bar = 100 μm. N = 3. The RORα-KO-MFC cells treated with 3PO (25 µM; 48 h) or DHEA (250 µM) were injected into subcutaneous flank of mice until the tumor volume reached 100 to 300 mm3.
-
Cell Prolif
Cathepsin K deficiency promotes alveolar bone regeneration by promoting jaw bone marrow mesenchymal stem cells proliferation and differentiation via glycolysis pathway. [Abstract]2021 Jul;54(7):e13058. PMID: 34053135 -
Pharmaceuticals (Basel)
Investigating the Role of Glycolysis in Xuefu Zhuyu Capsule-Promoted Angiogenesis in Endothelial Cells: A Study Based on Network Pharmacology, Molecular Docking, and In Vitro Validation. [Abstract]2025 Dec 17;18(12):1902. PMID: 41471391 -
Biomolecules
PFKFB3 Inhibitor 3PO Reduces Cardiac Remodeling after Myocardial Infarction by Regulating the TGF-β1/SMAD2/3 Pathway. [Abstract]2023 Jul 3;13(7):1072. PMID: 37509108 -
Int Immunopharmacol
Albiflorin contributes to Xuebijing-mediated protection against sepsis-associated acute kidney injury by modulating the succinate-PFKFB3 immunometabolic axis. [Abstract]2026 May 14:182:116841. PMID: 42134292 -
Am J Physiol Cell Physiol
Inflammation-induced PFKFB3-mediated glycolysis promoting myometrium contraction through the PI3K-Akt-mTOR pathway in preterm birth mice. [Abstract]2025 Feb 5. PMID: 39907705 -
mSystems
Inhibition of PFKFB3 in macrophages ameliorates intestinal inflammation by modulating gut microbiota in DSS-induced colitis. [Abstract]2025 Dec 11:e0063225. PMID: 41378888 -
Poult Sci
2024 Jun;103(6):103717. PMID: 38643746 -
Virol Sin
Thapsigargin suppresses porcine hemagglutinating encephalomyelitis virus replication by disrupting host energy metabolism. [Abstract]2025 Nov 21:S1995-820X(25)00161-0. PMID: 41276220 -
Fish Shellfish Immunol
Zinc oxide nanoparticles (ZnO-NPs) exhibit immune toxicity to crucian carp (Carassius carassius) by neutrophil extracellular traps (NETs) release and oxidative stress. [Abstract]2022 Oct:129:22-29. PMID: 35932984 -
ACS Chem Neurosci
Cdh1-Mediated Metabolic Switch from Pentose Phosphate Pathway to Glycolysis Contributes to Sevoflurane-Induced Neuronal Apoptosis in Developing Brain. [Abstract]2019 May 15;10(5):2332-2344. PMID: 30741526 -
Vet Res
Neospora caninum hijacks host PFKFB3-driven glycolysis to facilitate intracellular propagation of parasites. [Abstract]2025 Apr 30;56(1):94. PMID: 40307939 -
Food Chem Toxicol
Diacetoxyscirpenol-induced heterophil extracellular traps contribute to the immune toxicity of liver injury in chickens. [Abstract]2021 Feb:148:111926. PMID: 33352262 -
Toxicol Appl Pharmacol
PFKFB3 promotes endotoxemia-induced myocardial dysfunction through inflammatory signaling and apoptotic induction. [Abstract]2019 Apr 1:368:26-36. PMID: 30776389 -
J Inorg Biochem
Nanosilver-stimulated heterophil extracellular traps promoted liver and kidney injury in chicken. [Abstract]2022 Apr 20;233:111838. PMID: 35504082 -
Front Biosci (Landmark Ed)
Inhibition of PFKFB3 Expression Stimulates Macrophage-Mediated Lymphangiogenesis Post-Acute Myocardial Infarction. [Abstract]2023 Nov 3;28(11):277. PMID: 38062830 -
Vet Parasitol
2025 Apr 15:337:110471. PMID: 40245810 -
-
-
-
溶剤 & 溶解度
DMSO : 60 mg/mL (285.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3 mg/mL (14.27 mM); Clear solution
This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 3 mg/mL (14.27 mM); Clear solution
This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (279 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Clem B, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008 Jan;7(1):110-20. [Content Brief]
[2]. Schoors S, et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 2014 Jan 7;19(1):37-48. [Content Brief]
[3]. Lea MA, Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism. Anticancer Res. 2015 Nov;35(11):5889-99. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.7567 mL | 23.7835 mL | 47.5670 mL | 118.9174 mL |
| 5 mM | 0.9513 mL | 4.7567 mL | 9.5134 mL | 23.7835 mL | |
| 10 mM | 0.4757 mL | 2.3783 mL | 4.7567 mL | 11.8917 mL | |
| 15 mM | 0.3171 mL | 1.5856 mL | 3.1711 mL | 7.9278 mL | |
| 20 mM | 0.2378 mL | 1.1892 mL | 2.3783 mL | 5.9459 mL | |
| 25 mM | 0.1903 mL | 0.9513 mL | 1.9027 mL | 4.7567 mL | |
| 30 mM | 0.1586 mL | 0.7928 mL | 1.5856 mL | 3.9639 mL | |
| 40 mM | 0.1189 mL | 0.5946 mL | 1.1892 mL | 2.9729 mL | |
| 50 mM | 0.0951 mL | 0.4757 mL | 0.9513 mL | 2.3783 mL | |
| 60 mM | 0.0793 mL | 0.3964 mL | 0.7928 mL | 1.9820 mL | |
| 80 mM | 0.0595 mL | 0.2973 mL | 0.5946 mL | 1.4865 mL | |
| 100 mM | 0.0476 mL | 0.2378 mL | 0.4757 mL | 1.1892 mL |